Action SUPN SUPERNUS PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Supernus Pharmaceuticals, Inc.

Actions

SUPN

US8684591089

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 10/06/2024 		Varia. 5j. Varia. 1 janv.
26,19 USD -0,27 % Graphique intraday de Supernus Pharmaceuticals, Inc. -5,14 % -9,50 %
23/05 Transcript : Supernus Pharmaceuticals, Inc. - Special Call
08/05 Supernus Pharmaceuticals, Inc. recherche une fusion-acquisition CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
Supernus Pharmaceuticals Reports 'Clinical Utility' From Epilepsy Treatment Study
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Reports Q1 Revenue $143.6M, vs. Street Est of $145.8M
Supernus Pharmaceuticals, Inc. Seeks M&A
Supernus Announces First Quarter 2024 Financial Results
Supernus Pharmaceuticals, Inc. Reiterates Financial Guidance for the Full Year 2024
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Supernus, M8 Pharmaceuticals Sign Licensing Deal for ADHD Drug Qelbree in Latin America
M8 Pharmaceuticals, an Acino Company, Signs an Exclusive Licensing Agreement with Supernus for Qelbree® (Viloxazine Xr) in Latin America
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
Supernus Pharmaceuticals : 2023 Annual Report
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
Law Offices of Howard G. Smith Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
The Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action SUPN
  4. Actualités Supernus Pharmaceuticals, Inc.
  5. Autres langues